197 related articles for article (PubMed ID: 26003188)
1. CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia.
Ciszak L; Frydecka I; Wolowiec D; Szteblich A; Kosmaczewska A
Clin Exp Med; 2016 Aug; 16(3):317-32. PubMed ID: 26003188
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle regulatory proteins and apoptosis in B-cell chronic lymphocytic leukemia.
Wolowiec D; Ciszak L; Kosmaczewska A; Bocko D; Teodorowska R; Frydecka I; Kuliczkowski K
Haematologica; 2001 Dec; 86(12):1296-304. PubMed ID: 11726322
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27.
Decker T; Schneller F; Hipp S; Miething C; Jahn T; Duyster J; Peschel C
Leukemia; 2002 Mar; 16(3):327-34. PubMed ID: 11896535
[TBL] [Abstract][Full Text] [Related]
4. High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease.
Wolowiec D; Wojtowicz M; Ciszak L; Kosmaczewska A; Frydecka I; Potoczek S; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
Eur J Haematol; 2009 Apr; 82(4):260-6. PubMed ID: 19187271
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of cyclin D2 in chronic B-cell malignancies.
Delmer A; Ajchenbaum-Cymbalista F; Tang R; Ramond S; Faussat AM; Marie JP; Zittoun R
Blood; 1995 May; 85(10):2870-6. PubMed ID: 7742549
[TBL] [Abstract][Full Text] [Related]
6. Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 expression associated with progression in B-CLL.
Halina A; Artur P; Barbara MK; Joanna S; Anna D
Folia Histochem Cytobiol; 2010 Dec; 48(4):534-41. PubMed ID: 21478095
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin.
Decker T; Hipp S; Ringshausen I; Bogner C; Oelsner M; Schneller F; Peschel C
Blood; 2003 Jan; 101(1):278-85. PubMed ID: 12393642
[TBL] [Abstract][Full Text] [Related]
8. Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Pabst T; Peters UR; Tinguely M; Schwaller J; Tschan M; Aebi S; Vonlanthen S; Borisch B; Betticher DC; Zimmermann A; Tobler A; Fey MF
Leuk Lymphoma; 2000 May; 37(5-6):639-48. PubMed ID: 11042528
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phase.
Obermann EC; Went P; Tzankov A; Pileri SA; Hofstaedter F; Marienhagen J; Stoehr R; Dirnhofer S
J Clin Pathol; 2007 Jul; 60(7):794-7. PubMed ID: 16950856
[TBL] [Abstract][Full Text] [Related]
10. Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody.
Ciszak L; Frydecka I; Wolowiec D; Szteblich A; Kosmaczewska A
Tumour Biol; 2016 Mar; 37(3):4143-57. PubMed ID: 26490985
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases.
Sanhes L; Tang R; Delmer A; DeCaprio JA; Ajchenbaum-Cymbalista F
Leukemia; 2003 Jun; 17(6):1104-11. PubMed ID: 12764376
[TBL] [Abstract][Full Text] [Related]
12. Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.
Karabon L; Partyka A; Ciszak L; Pawlak-Adamska E; Tomkiewicz A; Bojarska-Junak A; Roliński J; Wołowiec D; Wrobel T; Frydecka I; Kosmaczewska A
J Immunol Res; 2020; 2020():6545921. PubMed ID: 32775467
[TBL] [Abstract][Full Text] [Related]
13. Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia.
Cobo F; Martínez A; Pinyol M; Hernández L; Gómez M; Beá S; Esteve J; Rozman M; Bosch F; López-Guillermo A; Montserrat E; Campo E
Leukemia; 2002 Jun; 16(6):1028-34. PubMed ID: 12040434
[TBL] [Abstract][Full Text] [Related]
14. Epstein-barr virus can infect B-chronic lymphocytic leukemia cells but it does not orchestrate the cell cycle regulatory proteins.
Maeda A; Bandobashi K; Nagy N; Teramoto N; Gogolák P; Pokrovskaja K; Székely L; Björkholm M; Klein G; Klein E
J Hum Virol; 2001; 4(5):227-37. PubMed ID: 11907380
[TBL] [Abstract][Full Text] [Related]
15. CTLA-4 regulates cell cycle progression during a primary immune response.
Greenwald RJ; Oosterwegel MA; van der Woude D; Kubal A; Mandelbrot DA; Boussiotis VA; Sharpe AH
Eur J Immunol; 2002 Feb; 32(2):366-73. PubMed ID: 11807776
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia.
Vrhovac R; Delmer A; Tang R; Marie JP; Zittoun R; Ajchenbaum-Cymbalista F
Blood; 1998 Jun; 91(12):4694-700. PubMed ID: 9616167
[TBL] [Abstract][Full Text] [Related]
17. BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells.
Banerji L; Glassford J; Lea NC; Thomas NS; Klaus GG; Lam EW
Oncogene; 2001 Nov; 20(50):7352-67. PubMed ID: 11704865
[TBL] [Abstract][Full Text] [Related]
18. Expression of cyclin E in resting and activated B-chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic target.
Decker T; Hipp S; Hahntow I; Schneller F; Peschel C
Br J Haematol; 2004 Apr; 125(2):141-8. PubMed ID: 15059135
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of interleukin-10 inhibition of T-helper cell activation by superantigen at the level of the cell cycle.
Perrin GQ; Johnson HM; Subramaniam PS
Blood; 1999 Jan; 93(1):208-16. PubMed ID: 9864163
[TBL] [Abstract][Full Text] [Related]
20. Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways.
Bogner C; Schneller F; Hipp S; Ringshausen I; Peschel C; Decker T
Exp Hematol; 2003 Mar; 31(3):218-25. PubMed ID: 12644019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
